Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
about
Molecularly targeted drugs for metastatic colorectal cancerModern Technologies for Creating Synthetic Antibodies for Clinical application.G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake.Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor InactivationFunction characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy.Research progress on criteria for discontinuation of EGFR inhibitor therapy.Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicityMolecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancerRemission of lung metastasis due to single nimotuzumab treatment: A preliminary observation and the first world report.Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab.Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockadePoly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells.The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction.Prostate specific antigen change after administration of nimotuzumab in prostate cancerSudden increased blood pressure and flu like symptom: An acute adverse reaction to nimotuzumab administration.
P2860
Q26828735-A0E40E06-AAEE-4588-BDD1-620CAE2B4899Q30467308-E578EA7C-9EE4-4D84-B332-6B7706D96C86Q33934981-7BA3EA79-104C-4662-83A8-582001557EBEQ34213559-1EB9837D-CF1B-4C55-8C65-EFAE5D33E3E7Q34451930-84A7065B-1937-44AF-B499-0C412202BA8EQ35855226-7C060582-8F41-489E-87A6-BED811C2DD8FQ36076031-86304C3D-D1DC-4B61-ADD4-4E46AB84993CQ36330264-4CBC11EF-675A-41D6-BB1D-74038757445BQ36332186-23E4E0F5-84C1-4A16-931F-5FD3116B1DE1Q37132173-02D9ECE5-8F3F-42F0-974B-E15975F2703DQ37150904-A355DE50-17C4-4118-B245-7DB216133B8EQ37317530-A322484B-034D-4234-9186-50FCE31FF74BQ37714248-06B6C273-BBD4-4B76-8BBD-4F4FBA9646FAQ37727996-24BEF257-A402-4B7D-ABC1-BAEA8BEDF247Q39805300-AA204279-B6AA-4B22-B7B7-104FFDCE7630Q39890007-F30CB536-C260-4FAB-B642-AC7698F370D2Q41485227-9AD89F70-A074-43E6-8374-74AEBD4F76F7Q41872970-086BA543-D0C9-44C1-BA16-2B30C689F3EFQ42587641-FC64A3A0-BE31-4663-98E8-E6E45B54BFB6
P2860
Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeted cancer therapies base ...... ptor: status and perspectives.
@en
type
label
Targeted cancer therapies base ...... ptor: status and perspectives.
@en
prefLabel
Targeted cancer therapies base ...... ptor: status and perspectives.
@en
P2860
P1476
Targeted cancer therapies base ...... ptor: status and perspectives.
@en
P2093
Zhenping Zhu
P2860
P304
P356
10.1111/J.1745-7254.2007.00681.X
P577
2007-09-01T00:00:00Z
P5875
P6179
1037726143